Welcome To The Resverlogix HUB On AGORACOM

**Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Cardiovascular Outcomes Trial and Will Soon Begin Phase 2a Kidney Dialysis and Phase 1 Fabry Disease Trials**

Free
AGORACOM NEWS FLASH

BREAKING NEWS!!!

Tartisan Resources Corp. to Acquire Canadian Arrow Mines Limited

 

  • Tartisan will acquire all of the issued and outstanding common shares of Canadian Arrow Mines Limited by way of a court-approved plan of arrangement
  • Tartisan would issue to Canadian Arrow Mines Limited shareholders one common share of Tartisan for every 17.5 common shares of Canadian Arrow, resulting in the issuance of approximately 8,000,000 common shares of Tartisan

 

Tartisan logo copy

Hub On AGORACOM / Read Release

Message: Q1 events list updated

One of the Q1 events is a Keystone Symposia (see event details below). Keystone Symposia are GREAT scientific meetings. Norm Wong presents on February 2nd discussing BET inhibitors in cardiovascular disease AND rheumatoid arthritis. It's been a while since we've heard from either Resverlogix or Zenith on their arthritis program. Hopefully that is a sign that the arthritis program is still alive and well.

 

Epigenetics and Human Disease: Progress from Mechanisms to Therapeutics

January 29—February 2, 2017

Sheraton Seattle Hotel, Seattle, Washington, USA

 

Thursday February 2

Norm Wong, Resverlogix Corporation, Canada 

Short Talk: Selective BET Inhibitors are Useful for Normalizing Inflammation Leading to Reduced Cardiovascular Disease (CVD) in Humans and in an Animal Model of Rheumatoid Arthritis

 

Share
New Message
Please login to post a reply